Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | lysophosphatidic acid receptor 3 | Starlite/ChEMBL | References |
Homo sapiens | lysophosphatidic acid receptor 1 | Starlite/ChEMBL | References |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 141 nM | Inhibitory concentration against Lysophosphatidic acid 1 (LPA1) receptor | ChEMBL. | 15225728 |
IC50 (binding) | = 141 nM | Inhibitory concentration against Lysophosphatidic acid 1 (LPA1) receptor | ChEMBL. | 15225728 |
Ki (binding) | = 64 nM | Binding affinity towards Lysophosphatidic acid 1 (LPA1) receptor | ChEMBL. | 15225728 |
Ki (binding) | = 64 nM | Binding affinity towards Lysophosphatidic acid 1 (LPA1) receptor | ChEMBL. | 15225728 |
Ki (binding) | = 1660 nM | Binding affinity towards Lysophosphatidic acid 3 (LPA3) receptor | ChEMBL. | 15225728 |
Ki (binding) | = 1660 nM | Binding affinity towards Lysophosphatidic acid 3 (LPA3) receptor | ChEMBL. | 15225728 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.